BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1512 related articles for article (PubMed ID: 33546958)

  • 1. COVID-19 in patients with cancer: Risks and precautions.
    Razavi A; Hamblin MR; Rezaei N
    Am J Emerg Med; 2021 Oct; 48():357-360. PubMed ID: 33546958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy.
    Hong R; Zhao H; Wang Y; Chen Y; Cai H; Hu Y; Wei G; Huang H
    Bone Marrow Transplant; 2021 Mar; 56(3):570-580. PubMed ID: 32943758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic.
    Bishop MR
    Clin Adv Hematol Oncol; 2020 Jul; 18(7):400-403. PubMed ID: 32903251
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
    Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
    Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
    Front Immunol; 2021; 12():589095. PubMed ID: 33995341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
    McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?
    Frigault MJ; Nikiforow S; Mansour MK; Hu ZH; Horowitz MM; Riches ML; Hematti P; Turtle CJ; Zhang MJ; Perales MA; Pasquini MC
    Blood; 2020 Jul; 136(1):137-139. PubMed ID: 32457999
    [No Abstract]   [Full Text] [Related]  

  • 12. Reactions Related to CAR-T Cell Therapy.
    Miao L; Zhang Z; Ren Z; Li Y
    Front Immunol; 2021; 12():663201. PubMed ID: 33995389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy.
    Li X; Shao M; Zeng X; Qian P; Huang H
    Signal Transduct Target Ther; 2021 Oct; 6(1):367. PubMed ID: 34667157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
    Xia L; Yuan LZ; Hu YH; Liu JY; Hu GS; Qi RY; Zhang TY; Xiong HL; Zheng ZZ; Lin HW; Zhang JM; Yu C; Zhou M; Ma J; Cheng T; Chen RR; Guan Y; Xia NS; Liu W
    Cell Mol Immunol; 2023 Apr; 20(4):351-364. PubMed ID: 36864189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytokine storm and COVID-19.
    Hu B; Huang S; Yin L
    J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients.
    Sesques P; Bachy E; Ferrant E; Safar V; Gossez M; Morfin-Sherpa F; Venet F; Ader F
    Cancer Cell; 2022 Mar; 40(3):236-237. PubMed ID: 35093212
    [No Abstract]   [Full Text] [Related]  

  • 17. CD8
    Bange EM; Han NA; Wileyto P; Kim JY; Gouma S; Robinson J; Greenplate AR; Hwee MA; Porterfield F; Owoyemi O; Naik K; Zheng C; Galantino M; Weisman AR; Ittner CAG; Kugler EM; Baxter AE; Oniyide O; Agyekum RS; Dunn TG; Jones TK; Giannini HM; Weirick ME; McAllister CM; Babady NE; Kumar A; Widman AJ; DeWolf S; Boutemine SR; Roberts C; Budzik KR; Tollett S; Wright C; Perloff T; Sun L; Mathew D; Giles JR; Oldridge DA; Wu JE; Alanio C; Adamski S; Garfall AL; Vella LA; Kerr SJ; Cohen JV; Oyer RA; Massa R; Maillard IP; Maxwell KN; Reilly JP; Maslak PG; Vonderheide RH; Wolchok JD; Hensley SE; Wherry EJ; Meyer NJ; DeMichele AM; Vardhana SA; Mamtani R; Huang AC
    Nat Med; 2021 Jul; 27(7):1280-1289. PubMed ID: 34017137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
    Root-Bernstein R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6: from arthritis to CAR-T-cell therapy and COVID-19.
    Kishimoto T
    Int Immunol; 2021 Sep; 33(10):515-519. PubMed ID: 33715009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
    Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 76.